Research Article

Increased Temperature Facilitates Adeno-Associated Virus Vector Transduction of Colorectal Cancer Cell Lines in a Manner Dependent on Heat Shock Protein Signature

Alicja Bienkowska,1 Weronika Kuźmicka,2,3 Olga Ciepiela,2 Justyn Ochocki,4 and Maciej Małecki1

1Department of Applied Pharmacy, Faculty of Pharmacy with Laboratory Medicine, Medical University of Warsaw, 1 Banacha Street, 02-097 Warsaw, Poland
2Department of Laboratory Medicine and Clinical Immunology of Developmental Age, Faculty of Medicine, Medical University of Warsaw, 63a Żwirki i Wigury Street, 02-091 Warsaw, Poland
3Postgraduate School of Molecular Medicine, Medical University of Warsaw, 61 Żwirki i Wigury Street, 02-091 Warsaw, Poland
4Department of Bioinorganic Chemistry, Medical University, 1 Muszynskiego Street, 90-150 Lodz, Poland

Correspondence should be addressed to Alicja Bienkowska; abienkowska@wum.edu.pl

Received 18 April 2019; Revised 30 July 2019; Accepted 10 August 2019; Published 8 February 2020

Academic Editor: Bo Zuo

Copyright © 2020 Alicja Bienkowska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Colorectal cancer (CRC) is one of the most common cancers in human population. A great achievement in the treatment of CRC was the introduction of targeted biological drugs and solutions of chemotherapy, combined with hyperthermia. Cytoreductive surgery and HIPEC (hyperthermic intraperitoneal chemotherapy) extends the patients’ survival with CRC. Recently, gene therapy approaches are also postulated. The studies indicate the possibility of enhancing the gene transfer to cells by recombinant adeno-associated vectors (rAAV) at hyperthermia. The rAAV vectors arouse a lot of attention in the field of cancer treatment due to many advantages. In this study, the effect of elevated temperature on the transduction efficiency of rAAV vectors on CRC cells with different origin and gene profile was examined. The effect of heat shock on the penetration of rAAV vectors into CRC cells in relation with the expression of HSP and AAV receptor genes was tested. It was found that the examined cells under hyperthermia (43°C, 1 h) are transduced at a higher level than in normal conditions (37°C). The results also indicate that studied RKO, HT-29, and LS411N cell lines express HSP genes at different levels under both 37°C and 43°C. Moreover, the results showed that the expression of AAV receptors increases in response to elevated temperature. The study suggests that increased rAAV transfer to CRC can be achieved under elevated temperature conditions. The obtained results provide information relevant to the design of new solutions in CRC therapy based on the combination of hyperthermia, chemotherapy, and gene therapy.

1. Introduction

Colorectal cancer (CRC) is one of the most common cancers in human population [1]. According to data from 2018, CRC is the second cause of oncology patient deaths in the world. The incidence and mortality rate of CRC in 2018 was above 1.8 million and nearly 0.9 million patients, respectively. Epidemiological studies indicate a continuous increase in cases of CRC [1]. At the same time, there is a dynamic progress in the field of explaining molecular mechanisms of CRC growth, defining predictors, as well as developing and implementing new drugs and therapeutic programs for patients [2–5]. The clinical centers especially administer drug programs based on fluoropyrimidine, leucovorin and oxaliplatin (5-fluorouracil-leucovorin-oxaliplatin, FOLFOX program) [6]. A great achievement was the introduction of targeted biological drugs to inactivate the key receptor/signaling proteins in CRC. The representative example is the presence in the clinics of cetuximab (anti-EGFR monoclonal antibody) and bevacizumab (anti-VEGF monoclonal antibody). These drugs, however, have functional limitations and very often numerous side effects. For example, cetuximab is most of all used in patients
with a nonmutated (wild type) KRAS gene [7, 8]. Moreover, in the CRC treatment area, solutions of chemotherapy combined with hyperthermia are introduced. It is indicated that the elevated temperature increases the therapeutic activity of the used cytotoxic drugs, especially in cases of peritoneal carcinomatosis [9, 10]. Increasing the permeability of tumor cell membranes, blood vessels and changes in the response of the immune system are emphasised among the postulated anti-neoplastic mechanisms of hyperthermia [11]. The importance of heat shock proteins (HSP) is highlighted in the response of tumor cells to hyperthermia and cytostatics are emphasised [12, 13]. Hyperthermia protocols include local application of elevated temperature or heating the whole body. Currently, nanotechnology proposes different ways of generating the phenomenon of hyperthermia, including laser, microwaves, radiofrequency, and ultrasound sources [14]. Great importance is attached to the development of the HIPEC strategy (hyperthermic intraperitoneal chemotherapy) [15]. Cytoreductive surgery and HIPEC extends the survival of patients with CRC [16, 17]. The results of a meta-analysis published recently by Desidero et al. including papers published in the last 30 years, showed that HIPEC significantly increases the survival time of patients with gastric cancers [18]. The number of new HIPEC clinical protocols in the field of CRC is growing [19, 20]. The possibilities of using the oncology hyperthermia strategy in increasing the effectiveness of cancer gene therapy based on recombinant adeno-associated vectors (rAAV) are also indicated [21–23]. Hyperthermia may induce both an increase in the expression of transgenes under the control of temperature-dependent inducible promoters [24, 25], and increase the vector transduction efficiency in a mechanism dependent on the HSP expression [22, 26]. Advances in understanding of CRC biology enable the development of ultra-modern drugs and therapies, which include gene transfer/correction strategies. Gene therapy is a promising proposition in cancer treatment. According to scientists, gene therapy based on the CRISPR-Cas9 method (localization and repair of damaged genes), lenivirus and adeno-associated virus vectors will play a key role in science and medicine in the coming years [27, 28]. Currently, cancer gene therapy strategies especially include suicide therapy, inhibition of angiogenesis, apoptosis stimulation, and modulation of immune response [29]. The development of gene transfer methods depends directly on progress in vectorology. Vectors based on rAAV arouse a lot of attention in the field of cancer treatment due to lack of pathogenicity, transduction of dividing and nondividing cells, selective tissue tropism, stable and long-term expression of the transgene [30–32]. In addition, it is suggested that rAAV have a natural tropism for colon cancer cells [33]. The current challenge in the field of rAAV vectors is to increase the efficiency of transduction through multiplying the applied dose of rAAV (MOI), using rAAV serotypes with defined organ tropism, chemical transduction modulators, e.g. proteasome inhibitors, and incorporating physicochemical procedures into the transduction [32]. Attention is drawn to research indicating the possibility of enhancing the transfer of rAAV genes by hyperthermia [21–23]. Due to the presence of hyperthermia in the treatment procedures of oncological patients, the design of clinical trials in cancer gene therapy should consider the possibility of increasing the efficiency of rAAV transduction through heat shock. Moreover, the observed gene signatures of cancer cells exposed to hyperthermia facilitates the introduction to oncological clinics of new therapeutic solutions, such as cancer gene therapy based on rAAV vectors.

The present study investigates the effect of elevated temperature (conditions imitating the oncological hyperthermia) on the transduction of rAAV vectors to CRC with different origin and gene profile. The effect of heat shock on the penetration of rAAV vectors into CRC cells in relation to the expression of key genes determining carcinogenicity and rAAV transduction was investigated. Emphasis was placed on the expression of HSP genes. The work provides essential information to the design of new solutions in CRC therapy based on the combination of hyperthermia, chemotherapy, and gene therapy.

2. Materials and Methods

2.1. Cell Lines. The following human colon cancer cell lines, part of Colon Cancer Panel 2, BRAF (ATCC® TCP-1007™, American Type Culture Collection, Manassas, VA, USA) were included in the present study: HT-29 (ATCC® HTB-38™), LS411N (ATCC® CRL-2159™), RKO (ATCC® CRL-2577™) and CCD-18Co (ATCC® CRL-1459™) human colon fibroblast. HT-29 were cultured in McCoy’s 5a Medium Modified (Sigma-Aldrich, St. Louis, MO, USA), LS411N–RPMI-1640 Medium (Gibco, Thermo Fisher Scientific, Waltham, MA, USA), RKO–Dulbecco’s Modified Eagle Medium (DMEM; Gibco, Thermo Fisher Scientific), CCD-18Co–Minimum Essential Medium (MEM; Gibco, Thermo Fisher Scientific). The media were supplemented with 10% FBS (Gibco, Thermo Fisher Scientific) and 1% Antibiotic–Antimycotic (Gibco, Thermo Fisher Scientific). The cells were maintained at 37°C in a humidified 5% CO₂ atmosphere.

2.2. rAAV Transduction at Hyperthermia. Cells were seeded at the density of 6.5 × 10⁴ for HT-29 and LS411N, 3.5 × 10⁴ for RKO and 10.0 × 10⁴ for CCD-18Co per well in six-well plates (Nunc, Thermo Fisher Scientific) in dedicated medium. After 24 h incubation at a normal culture condition, cell lines were transduced. The recombinant AAV vector AAV/DJ-CAG-GFP (Cat. No. 7078; Vector Biolabs, Malvern, PA, USA) was used with the multiplicity of infection (MOI) of 4 × 10⁴ genome copies. The AAV/DJ is a mosaic serotype made with genetic engineering methods from eight wild types of AAV serotypes, including AAV2, 4, 5, 8, 9, avian, bovine, and goat AAV. The vector expresses eGFP (green fluorescent protein) under the control of CAG promoter, which is a hybrid of the cytomegalovirus (CMV) early enhancer element and chicken beta-actin promoter [34]. Before transduction, the cell culture media were replaced with dedicated media heated up to 37°C or 43°C enriched with 2% FBS. Transduction was performed in two variants. The first option consisted in incubating cells for 1 h at 43°C, then rAAV was introduced to the media. The second variant began with adding the vectors to the media; then the plate was shaken at 300 rpm in a 5 × 4 minute system, with
2.3. Measurement of Transduction Efficiency. The inverted fluorescence microscope (Olympus IX53, Olympus, Tokyo, Japan) with the pE-300 white (CoolLED, Andover, MA, USA) illumination system was used to obtain the images of cells expressing Green Fluorescent Protein (GFP). Pictures of nontransduced (in BP) and transduced (in FITC) cells were taken at 10x magnification. The percentage of GFP positive cells was determined with the use of The Countess II FL Automated Cell Counter (Invitrogen, Thermo Fisher Scientific) with EVOS Light Cube–GFP (470/22 nm Excitation; 510/42 nm Emis) fluorescence microscope (Olympus IX53, Olympus, Tokyo, Japan) with the pE-300 white (CoolLED, Andover, MA, USA) illumination system. Flow cytometry (LSR Fortessa, Becton Dickinson, Franklin Lakes, NJ, USA) was used to determine cell viability and transduction efficiency by FITC detector. Percentage of transduced cells was analyzed based on the level of green fluorescent protein expression (FITC detector).

All GFP+ cell measurements were performed on the 7th day of the experiment, then the cells were harvested for DNA isolation to analyze the transduction efficiency by qPCR.

2.4. Real-Time PCR for Determination of AAV Genome Copy Number. Total DNA was isolated using the High Pure Viral Nucleic Acid Kit (Roche Life Science, Mannheim, Germany). To determine the rAAV genome copy number, TaqMan assays were designed using a probe and primers for the ITR region. The TaqMan probe (5'–CACTCCCTCTCTGCGCGCTCG-3') featured 6-FAM and TAMRA. The forward primer was 5'–GGAACCCCTAGTGAAGAGTT-3' and the reverse primer was 5'–CGGCCTCAGTGAGGTTGAGTT-3'. Standard curve was created using plasmid DNA pAAV-hrGFP (Part No. 240074; Agilent Technologies). Total volume of qPCR reactions was 10µl, contained 50 ng DNA and ran under the following conditions: 50°C for 2 minutes, 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds, and 60°C for 60 s. Real-time PCR was performed in StepOnePlus™ Real-Time PCR System (Applied Biosystems, Thermo Fisher Scientific). The rAAV genome copy number was normalized as viral genome copy number/50 µg of total genomic DNA.

2.5. Reverse Transcription PCR and Real-Time PCR. Total RNA was isolated [36] using the TRI Reagent (Sigma-Aldrich, St. Louis, MO, USA) to test gene expression. The contaminating DNA in RNA samples was removed with the use of DNA-free™ DNA Removal Kit (Invitrogen, Thermo Fisher Scientific). The High Capacity RNA-to-cDNA kit (Applied Biosystems, Thermo Fisher Scientific) was used to synthesize single-stranded cDNA.

All samples of CCD-18Co maintained at 37°C were selected as a reference sample in the ΔΔCt method [37]. The TaqMan Array 96–Well FAST Plate Human Heat Shock Proteins (Cat. No. 4418733; Applied Biosystems, Thermo Fisher Scientific) was used to examine the expression of HSP in studied cell lines, 24 h after exposure to 37°C and 43°C for 1 h. Samples of CCD-18Co maintained at 37°C were selected as a reference sample in the ΔΔCt method [37].

Gene expression levels of target genes were normalized to the level of housekeeping genes encoding: β-actin (ACTB) for AAV transmission genes, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for HSP. All qPCR reactions were performed based on manufacturer instructions in the StepOnePlus™ Real-Time PCR System. The Expression Suite Software v1.1 (Thermo Fisher Scientific) was used to calculate relative gene expression levels by the ΔΔCt method [37].
**Figure 2:** Transduction efficiency of RKO cells. The studied cells were transduced with the rAAV/DJ vector at hyperthermia conditions (as described at M&M panel). The GFP (Green Fluorescent Protein) positive (+) cells were measured by the Countess II FL Automated Cell Counter and the qPCR method (panel (a)), flow cytometry (panel (b)), and visualized with an inverted fluorescence microscope (panel (c)). For panel b the Q1 and Q2 quadrants represent death cells (7-AAD positive staining). The Q3 and Q4 quadrants represent live cells (7-AAD negative staining). The GFP+ cells are located in Q2 and Q4 quadrants. Images of non-transduced (BF) cells and transduced cells (FITC) were performed at 10x magnification (panel (c)). Statistically significant differences were analyzed between cells transduced at 37°C and cells transduced at hyperthermia conditions. Statistical significance for results of GFP+ cells were marked as asterisks ($^{\ast\ast}p < 0.01$; $^{\ast\ast\ast\ast}p < 0.0001$) and for results of rAAV genome copies (gc) were marked as carets ($^{^\circ\circ}p < 0.01$; $^{^\circ\circ\circ\circ}p < 0.0001$).
Transduction efficiency of HT-29 cells. The studied cells were transduced with the rAAV/DJ vector at hyperthermia conditions (as described at M&M panel). The GFP (Green Fluorescent Protein) positive (+) cells were measured by the Countess II FL Automated Cell Counter and the qPCR method (panel (a)), flow cytometry (panel (b)), and visualized with an inverted fluorescence microscope (panel (c)). For panel b the Q1 and Q2 quadrants represents death cells (7-AAD positive staining). The Q3 and Q4 quadrants represents live cells (7-AAD negative staining). The GFP+ cells are located in Q2 and Q4 quadrants. Images of non transduced (BF) cells and transduced cells (FITC) were performed at 10x magnification (panel (c)). Statistically significant differences were analyzed between cells transduced at 37°C and cells transduced at hyperthermia conditions. Statistical significance for results of GFP+ cells were marked as asterisks (** \( p < 0.01 \); *** \( p < 0.001 \)) and for results of rAAV genome copies (gc) were marked as carets (^^ \( p < 0.01 \)).
F/i.sc/g.sc/u.sc/r.sc/e.sc 4: Transduction efficiency of LS411N cells. The studied cells were transduced with the rAAV/DJ vector at hyperthermia conditions (as described at M&M panel). The GFP (Green Fluorescent Protein) positive (+) cells were measured by the Countess II FL Automated Cell Counter and the qPCR method (panel (a)), flow cytometry (panel (b)), and visualized with an inverted fluorescence microscope (panel (c)). For panel b the Q1 and Q2 quadrants represents death cells (7-AAD positive staining). The Q3 and Q4 quadrants represents live cells (7-AAD negative staining). The GFP+ cells are located in Q2 and Q4 quadrants. Images of non transduced (BF) cells and transduced cells (FITC) were performed at 10x magnification (panel (c)). Statistically significant differences were analyzed between cells transduced at 37°C and cells transduced at hyperthermia conditions. Statistical significance for results of GFP+ cells were marked as asterisks (** p < 0.0001).
Transduction efficiency CCD-18Co

| Temperature | GFP+ cells (%) |
|-------------|----------------|
| 37°C (20')  | Control       |
| 43°C        | AAV/DJ        |
| 37°C (5 × 4') |               |

Transduction efficiency of CCD-18Co cells. The studied cells were transduced with the rAAV/DJ vector at hyperthermia conditions (as described at M&M panel). The GFP (Green Fluorescent Protein) positive (+) cells were measured by the Countess II FL Automated Cell Counter and the qPCR method (panel (a)), flow cytometry (panel (b)), and visualized with an inverted fluorescence microscope (panel (c)). For panel b the Q1 and Q2 quadrants represents death cells (7-AAD positive staining). The Q3 and Q4 quadrants represents live cells (7-AAD negative staining). The GFP+ cells are located in Q2 and Q4 quadrants. Images of non transduced (BF) cells and transduced cells (FITC) were performed at 10x magnification (panel (c)). Statistically significant differences were analyzed between cells transduced at 37°C and cells transduced at hyperthermia conditions. Statistical significance for results of GFP+ cells were marked as asterisks (\( ^* p < 0.01 \)) and for results of rAAV genome copies (gc) were marked as carets (\( ^\wedge p < 0.05 \)).
The statistical significance is marked as $p < 0.05$ and $p < 0.01$. Under basic conditions (37°C), cells transduce at a lower level. In the study, the sequential exposure of cells to hyperthermia was also performed. A cycle with five 4-minute temperature shocks (43°C) was used. As shown in Figures 2–5, the procedure did not reveal significant differences in the number of GFP+ cells, excluding LS411N cells (an increase from 7% to 11% GFP+; Figure 4). The copy number of the rAAV/DJ vectors, assessed by the qPCR method, provides interesting information about the efficiency/mechanisms of CRC cell transduction at hyperthermia. Generally, the number of determined rAAV genome copies (gc) corresponds to the transduction efficiency and the number of GFP+ cells (Figures 2–5). It is intriguing that in e.g. the LS411N line with lower transduction efficiency (12% GFP+) a relatively high rAAV copy number (5.3E+06 gc) was shown. A similar copy number was obtained for the HT-29 line (6.4E+06) but in that case, transduction efficiency was estimated at 30% GFP+. Equally, for the CCD-18Co line the number of transduced cells (34% GFP+) corresponds to 5.1E +06 gc of rAAV. However, RKO cells transduced at the level of 40% (40% GFP+) with the rAAV copy number being estimated at only 1.2E +05 gc. The obtained results suggest the possibility of different mechanisms of transmission/metabolism of rAAV.

### 3. Results

#### 3.1. rAAV Transduction of Colorectal Cancer Cells at Hyperthermia Conditions

The efficiency of the transduction of cancer cells RKO, HT-29, LS411N, and CCD-18Co fibroblasts was evaluated by counting GFP+ cells with an automated cell counter with fluorescence detection, flow cytometer, and by assessment of the rAAV copy number with qPCR. The results are shown in the Figures 2–5. To analyze expression of GFP, the cells were harvested 6 days after transduction. As shown in Figures 2–5, the exposure of CRC cells to elevated temperature (43°C, hyperthermia) results in an increase in the rAAV transduction efficiency. The examined cells under hyperthermia are transduced at a higher level than in the normal conditions at 37°C. The tests performed with an automated fluorescence cell counter and FACS, respectively, showed that transduction efficiency in the elevated temperature reached 40%/51% for RKO, 30%/29% for HT-29, 10%/6% for LS411N, and 34%/36% for CCD-18Co. The viability of cells subjected to heat shock was determined as 95–98%. Under basic conditions (37°C) cells transduce at a lower level.

#### 3.2. Expression of rAAV Receptors at Hyperthermia Conditions

The expression analysis of representative AAV receptor genes (AAVR, HSPG1, HSPG2) was performed with the qPCR method with the use of TaqMan probes. As shown in Figures 6 and 7, the examined cell lines are characterized by a different expression pattern of the rAAV transmission genes in both constitutive (37°C) and hyperthermia (43°C) conditions. In the context of the search for mechanisms to increase the number of GFP+ cells after exposure to heat shock, it is interesting that the expression of AAV receptors was changed in the CRC cells in response to elevated temperature. Outstanding results were obtained especially for AAVR and HSPG2 genes. As shown in Figure 2, the RKO cells are most efficiently transduced rAAV at hyperthermia (40% GFP+) which correspond to the highest increase in the expression of AAVR and HSPG2 genes. The upregulation of AAVR and HSPG2 expression was also observed for the HT-29 and LS411N cell lines, but at a lower level which may correspond to lower transduction efficiency, 30% GFP+ and 10% GFP+, respectively. Figures 6 and 7 also present the expression of AAV receptors in CCD-18Co control cells. The results show that CCD-18Co fibroblasts have a specific gene signature of AAV receptors that is different than in CRC cells. The presence of HSPG1 gene expression is characteristic. CCD-18Co cells respond to hyperthermia with increase in expression of all three AAV receptors.

#### 3.3. HSP Expression at Normal and Hyperthermia Conditions

Analysis of HSP gene expression was performed with the use of TaqMan Array Human Heat Shock Proteins. Expression levels of 42 HSP genes representing key members of HSP27, HSP40, HSP70, HSP90 families were assessed. The constitutive expression (37°C) and expression after exposure to hyperthermia (43°C) were evaluated. The results are shown in Figures 8 and 9. The potential functional
expression. Based on the obtained results, it is possible to propose specific HSP expression signatures characteristic for the tested CRC lines and potentially responsible for rAAV transduction under hyperthermia. The cells most efficiently transduced with rAAV, RKO (40% GFP+) after exposure to hyperthermia are characterized mainly by an increase in the expression of HSP genes. The results indicate that the investigated RKO, HT-29, and LS411N cell lines express HSP genes at different levels under both 37°C (Figure 8) and 43°C (Figure 9). Under the hyperthermia conditions cells respond with visible changes in HSP expression. The figure shows relevant differences between constitutive expression of HSP (2^{−ΔΔCt}).

Figure 7: AAVR, HSPG1 and HSPG2 expression in CRC lines. The influence of heat shock on the expression of genes in tested cells as well as normal cells was estimated by the reverse transcription and the qPCR method. The cells not exposure to hyperemia were used as reference to calculate fold range (2^{−ΔΔCt}). Statistically significant differences were analyzed between cells incubated at 37°C and cells exposed to hyperthermia conditions (**p < 0.01; ****p < 0.0001).
BioMed Research International

thousand clinical trials of gene therapy have been performed in the world, including almost 240 involving rAAV vectors [39]. It is also known that gene preparations are included in classic oncological treatment protocols [31, 40]. The therapeutic effectiveness of gene therapy is inextricably linked to the efficiency of gene transfer to target cells. The type of vector used, the vector titer (dose), and extracellular and intracellular transduction barriers influence the gene transfer [41, 42].

In the current study, attention was paid to the possibility of increasing the transduction efficiency with rAAV vectors to CRC cells by hyperthermia. Our tests were performed based on the rAAV mosaic vector (rAAV/DJ), which expresses GFP under a strong CAG promoter. As shown in Figures 2–5, elevated temperature conditions increase the efficiency of rAAV transduction. The percentage of GFP+ cells is higher in hyperthermia conditions. In general, the stimulating effect of elevated temperature on rAAV transduction efficiency was observed for all three CRC tested (RKO, HT-29, LS411N). Differences between percentages of GFP+ cells between lines were observed. The most efficiently transduced in hyperthermia were RKO (40%), then HT-29 (30%) and LS411N has the lowest level (10%). The study also evaluated the level of rAAV/DJ genome copies in transduced cells. Due to the high transduction efficiency of RKO cells (40% GFP+) with a simultaneously low rAAV number (1.2E₅ gc), it can be speculated that hyperthermia involves potential intracellular rAAV degradation mechanisms in CRC cells. For LS411N cells, however, an inverse effect was observed, i.e., with a low GFP+ cell count (10%) the number of rAAV copies was relatively high (5.3E₆).

Levels of DNAJC4, HSPA5, HSPA8, and HSPB1. HT-29 cells (30% GFP+) are characterized especially by increased levels of DNAJC4, HSP90AB1, HSPA2, HSPA5, HSPA9, and HSF4 upon exposure to hyperthermia. LS411N cells with the lowest efficiency of rAAV transduction (10% GFP+) after exposure to hyperthermia are characterized mostly by HSPA2 and HSPA6. Control CCD-18Co cells (34% GFP) are characterized in 43°C mainly by expression of HSPA2, HSPA5, HSPA8, and HSPB1. The obtained HSP expression signatures confirm the information that CRC are not molecularly a homogeneous group of neoplastic diseases; therefore, they may respond differently to temperature shock. The results allow a better understanding of the mechanisms of rAAV transduction under hyperthermia. Potential relationships between rAAV transduction, AAV receptor, and HSP expression are collected in Table 1.

4. Discussion

In the presence of the serious global data on the incidence and mortality of CRC, the need for research of new treatment solutions is obvious and extremely urgent. The formula of personalized medicine is particularly visible and up-to-date in CRC. Personalized medicine considers the potential of ultrasensitive medical diagnosis methods as well as the presence of targeted medications. It appears that in the beginning gene therapy was based on primarily treating the causes of diseases and perfectly fulfills the requirements of personalized medicine. Over two thousand clinical trials of gene therapy have been performed in the world, including almost 240 involving rAAV vectors [39]. It is also known that gene preparations are included in classic oncological treatment protocols [31, 40]. The therapeutic effectiveness of gene therapy is inextricably linked to the efficiency of gene transfer to target cells. The type of vector used, the vector titer (dose), and extracellular and intracellular transduction barriers influence the gene transfer [41, 42].

In the current study, attention was paid to the possibility of increasing the transduction efficiency with rAAV vectors to CRC cells by hyperthermia. Our tests were performed based on the rAAV mosaic vector (rAAV/DJ), which expresses GFP under a strong CAG promoter. As shown in Figures 2–5, elevated temperature conditions increase the efficiency of rAAV transduction. The percentage of GFP+ cells is higher in hyperthermia conditions. In general, the stimulating effect of elevated temperature on rAAV transduction efficiency was observed for all three CRC tested (RKO, HT-29, LS411N). Differences between percentages of GFP+ cells between lines were observed. The most efficiently transduced in hyperthermia were RKO (40%), then HT-29 (30%) and LS411N has the lowest level (10%). The study also evaluated the level of rAAV/DJ genome copies in transduced cells. Due to the high transduction efficiency of RKO cells (40% GFP+) with a simultaneously low rAAV number (1.2E₅ gc), it can be speculated that hyperthermia involves potential intracellular rAAV degradation mechanisms in CRC cells. For LS411N cells, however, an inverse effect was observed, i.e., with a low GFP+ cell count (10%) the number of rAAV copies was relatively high (5.3E₆).
the reaction of CRC cells to rAAV under hyperthermia. The gene expression patterns of the tested cells (AAV receptors and HSP) correspond to the increase of rAAV transduction at elevated temperatures. As shown in Figure 7, in cells stimulated under hyperthermia, the expression of AAVR and HSPG2 genes increased predominantly. In the presence of the recently described key role of AAVR in the transduction of rAAV [43], the obtained results can be considered as interesting information. The increase in the number of GFP+ cells observed at an elevated temperature is in relation to significant contribution in the rAAV cellular transmission of the transmembrane protein (KIAA0319L) defined as AAVR, demonstrated by Pillay et al. [44–46].

In rAAV transduction cells, the role of immunophilin proteins is indicated. Immunophilins belong to highly conserved immunosuppressive drug-binding proteins, such as FK506 (tacroimus). FK506-binding proteins (FKBPs) are representative proteins for immunophilins. FKBPs act as cellular chaperones [47, 48]. An example of a protein that acts as a chaperone is FKBP52. Qing et al. [23] showed that the adeno-associated virus D-sequence-binding protein is a FKBP52. Subsequent work clarified the role of FKBP52 in the transduction of rAAV by determining the contribution of HSP [21, 23]. The works of Zhong et al. [21] and Zhao et al. [22] showed to increase the efficiency of rAAV transduction at a higher temperature in gc) suggesting that LS411N cells are more resistant to potential rAAV degradation stimulated by hyperthermia. On the other hand, HT-29 cell line transduced in 30% yield (GFP+), and the rAAV copy number was estimated at 6.4E+06 gc (Figure 3). The increase of rAAV transduction efficiency in response to the increased temperature was also demonstrated in the work of other authors. The publication of Zhong et al. [21] showed that 4h exposure of Hela cells to a temperature of 42.5°C caused about 6x increase in rAAV transduction efficiency. In this study, 1h stimulation at 43°C was used in different combinations. The cells were subjected to one-time 1h exposure to 43°C or a thermal shock procedure was applied (see M&M). However, the mentioned shock cycle method, as shown in Figures 2–5, do not introduce significant differences in the number of GFP+ cells.

Looking at the potential mechanisms of the increase in the number of GFP+ cells, the obtained results were analyzed in relation to the evaluated expression of AAV receptor and HSP genes (Table 1). The signatures of both AAV receptor genes and HSP are different for the tested CRC lines. String diagrams (Figure 10) show the possible functional associations between the proteins of the examined transcripts (HSP and AAV receptors). The obtained results show hyperthermia induces changes in the expression of selected genes. It can be postulated that the assessed transcript signatures determine

---

**Figure 10**: Networks of upregulated genes after hyperthermia was applied to CRC cell lines and colon fibroblast (based on data from Table 1). The interactions were visualized as nodes and colored edges (according to String database [38]).
connection with the expression of selected HSP and FKBP52 genes. It was observed that phosphorylated FKBP52 interacts with D-sequences in inverted terminal repeats of adenovirus 2 genome, which consequently leads to inhibition of the second strand of AAV DNA synthesis, and further to inefficient expression of reporter transgenes, i.e. a decrease in transduction efficiency.

In the present study a broader assessment of the HSP gene expression in cells exposed to elevated temperature in relation to the transduction efficiency of AAV was attempted. A panel of 42 transcripts of HSP mRNAs representing the key HSP families HSP27, HSP40, HSP70, HSP90 was evaluated (Figure 8). Differences in constitutive as well as heat-stimulated HSP expression were demonstrated. During analysis of HSP profiles, we concentrated on proteins potentially involved in the interaction with FKBP and thereby involved in the transduction/expression of rAAV. As reported in the other works [21, 22], the efficiency of tumor cell transduction by rAAV can be limited by the expression of FKBP52 and interactions with HSP90. Furthermore, we paid attention to HSPA2 and HSPA6 in obtained HSP profile, due to the defined interactions with FKBP6 (FKBP36), chaperone protein in the immunophilin family [49]. As shown in Figure 9, CRC cells have different levels of HSPA2 and HSPA6, which may be in relation to the level of transduction at an elevated temperature and the potentially low number of rAAV gene copies in RKO cells (Figure 2). In the context of understanding the mechanisms of viral vector transduction into cells, it is interesting to notice that silencing of the FKBP6 gene enhances HIV-1 replication in HeLa-CD4 cells infected with viral pseudotypes HIV89.6R and HIV8.2N [50]. It can be speculated that the potential mechanism of FKBP6 participation in rAAV transduction may be comparable to that described for HIV-1. FKBP6 can also interact with clathrin and HSP72, HSP90AA, HSP90AA5P, and HSP90AB1 [51, 52].

Due to the participation of HSP in the development of cancers, HSP inhibitors are investigated as new factors supporting anti-cancer therapies [13]. Based on the information on the influence of HSP in the vector transfer to cells in gene therapy, it is possible to see the application of HSP inhibitors in enhancing the efficiency of cancer gene therapy. Similarly, when looking for mechanisms regulating the transfer of rAAV, attention is also paid to contribution in the rAAV transduction of the small proteins termed as SUMO and SUMOylation pathways. Holscher et al. [53] indicate the participation of SUMOylation in the transduction of rAAV. According to the authors, modulation of SUMOylation by interacting with the main system proteins (E1 conjugation enzyme Ubc9 and E3 enzymes) may increase the efficiency of transduction of rAAV. It is also indicated that HSP, e.g., HSP27, may be involved in modifications of other proteins with the participation of SUMO-2/3 [54], which may suggest a significant contribution of HSP-SUMO pathways in the transduction of rAAV.

Hyperthermia is a method of increasing the effectiveness of therapeutic protocols used in oncology [10]. Current nanomedicine is based on the use of recombinant viral particles or vectors commonly used in gene therapy strategies. The attractive biochemical-physical characteristics of rAAV, like small size, organ tropism, and nonpathogenicity [55], favor the introduction of rAAV for the treatment. Glybera and Luxturna are examples of commercialized gene therapeutics [56]. The current challenge in the field of rAAV vectorology is directly linked to increasing the efficiency of cell transduction. Efficient gene transfer to CRC cells would allow a combination of classic protocols for oncological treatment such as hyperthermic intraperitoneal chemotherapy (HIPEC) with gene therapy.

5. Conclusion

The present study suggests that increased rAAV transfer to CRC cells can be obtained under elevated temperature conditions. Finally, we postulate that the response of CRC cells to rAAV in hyperthermia is related with specific AAVR and HSP gene signatures.
Data Availability
The datasets used to support the findings of the current study are available from the corresponding author upon reasonable request.

Conflicts of Interest
The authors declare that there are no conflicts of interest regarding the publication.

Acknowledgments
This work was supported by the National Centre for Research and Development grant (Strategmed/233264/4/NCBR/2014, MentorEYE) and partially by the Medical University of Lodz grant (503/3/-016-02/503-31-001).

References
[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jamal, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.
[2] M. Wright, I. S. Beatty, and C. A. Ternent, "Molecular Markers for colorectal cancer," Surgical Clinics of North America, vol. 97, no. 3, pp. 683–701, 2017.
[3] S. Stintzing, "Recent advances in understanding colorectal cancer," F1000Research, vol. 7, 2018, Faculty Rev-1528.
[4] K. Matlawa, U. Kalinowska, A. Erxleben, R. Osiecka, and J. Ochocki, "Novel analogues of 5-flourouracil–synthesis, x-ray crystallography, and cytotoxic effects in normal human peripheral blood lymphocytes and colon adenocarcinoma HT 29," European Journal of Inorganic Chemistry, vol. 2005, no. 15, pp. 3109–3117, 2005.
[5] J. Ochocki, A. Andrea Erxleben, and B. Lippert, "Synthesis and spectroscopy of phosphonate derivatives of uracil and thymine. X-ray crystal structure of diethyl 6-uracilmethylphosphonate," Journal of Heterocyclic Chemistry, vol. 34, pp. 1179–1184, 1997.
[6] Y. S. Hong, B. H. Nam, K. P. Kim et al., "Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial," The Lancet Oncology, vol. 15, no. 11, pp. 1245–1253, 2014.
[7] L. Bai, F. Wang, Z. Z. Li et al., "Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: results of a registry-based cohort analysis," Medicine (Baltimore), vol. 95, no. 51, p.e4531, 2016.
[8] A. P. Venook, D. Niedzwiecki, H. J. Lenz et al., "Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial," JAMA, vol. 317, no. 23, pp. 2392–2401, 2017.
[9] M. D. Goodman, S. McPartland, D. Detelich, and M. W. Saif, "Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy," Journal of Gastrointestinal Oncology, vol. 7, no. 1, pp. 45–57, 2016.
[10] A. Kheirolooomoon, C.-Y. Lai, S. M. Tam et al., "Complete regression of local cancer using temperature-sensitive liposomes combined with ultrasound-mediated hyperthermia," Journal of Controlled Release, vol. 172, no. 1, pp. 266–273, 2013.
[11] N. van den Tempel, M. R. Horsman, and R. Kanaar, "Improving efficacy of hyperthermia in oncology by exploiting biological mechanisms," International Journal of Hyperthermia, vol. 32, no. 4, pp. 446–454, 2016.
[12] J. O. Pelz, M. Vetterlein, T. Grimmig et al., "Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: role of heat shock proteins and dissecting effects of hyperthermia," Annals of Surgical Oncology, vol. 20, no. 4, pp. 1105–1113, 2013.
[13] F. Sauvage, S. Messaoudi, E. Fattal, G. Barratt, and J. Vergnaud-Gauduchon, "Heat shock proteins and cancer: how can nanomedicine be harnessed?" Journal of Controlled Release, vol. 248, pp. 133–143, 2017.
[14] J. Beik, Z. Abed, F. S. Ghoreishi et al., "Nanotechnology in hyperthermia cancer therapy: from fundamental principles to advanced applications," Journal of Controlled Release, vol. 235, pp. 205–221, 2016.
[15] P. H. Sugarbaker and K. Van der Speeten, "Surgical technology and pharmacology of hyperthermic peripharotic chemotherapy," Journal of Gastrointestinal Oncology, vol. 7, no. 1, pp. 29–44, 2016.
[16] V. J. Verwaal, S. van Ruth, E. de Bree et al., "Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer," Journal of Clinical Oncology, vol. 21, no. 20, pp. 3737–3743, 2003.
[17] P. Piso, K. Stierstorfer, M. Gerken, and M. Klinkhammer-Schalke, "Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer," International Journal of Colorectal Disease, vol. 33, no. 11, pp. 1559–1567, 2018.
[18] J. Desiderio, J. Chao, L. Melstrom et al., "The 30-year experience – a meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer," European Journal of Cancer, vol. 79, pp. 1–14, 2017.
[19] A. Arjona-Sánchez, P. Barrios, E. Boldo-Roda et al., "HIPEC'T4: multicentre, randomized clinical trial to evaluate safety and efficacy of hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma," BMC Cancer, vol. 18, no. 1, p. 183, 2018.
[20] C. E. Klaver, G. D. Musters, W. A. Bemelman et al., "Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial," European Journal of Cancer, vol. 32, no. 1, pp. 205–221, 2016.
Human Gene Therapy Methods
time PCR for the detection and quantification of adeno-associated C. A
K. Qing
A. Srivastava, "Adeno-associated virus type 2-mediated gene
, vol. 75, no. 19, pp. 8968–8976, 2001.

D613, 2019.

S. P. Tu, J. T. Cui, P. Liston et al., "Gene therapy for colon cancer
Molecular Biology Journal of AAV-host interactions: the fast and the curious, 
Journal of Controlled Release (AAV) vectors in cancer gene therapy, 
Journal of Controlled Release

K. J. Chang, T. Reid, N. Senzer et al., "Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer," Gastrointestinal Endoscopy, vol. 75, no. 6, pp. 1139–1146.e2, 2012.

C. E. Thomas, A. Ehrhardt, and M. A. Kay, "Progress and problems with the use of viral vectors for gene therapy," Nature Reviews Genetics, vol. 4, no. 5, pp. 346–358, 2003.

K. Lundstrom, "Viral vectors in gene therapy," Diseases, vol. 6, no. 2, p. 42, 2018.

S. Sun and D. V. Schaffer, "Viral infection: a key host receptor for AAV," Nature Microbiology, vol. 1, no. 3, 2016.

S. Pillay, N. L. Meyer, A. S. Puschnik et al., "An essential receptor for adeno-associated virus infection," Nature, vol. 530, no. 7588, pp. 108–112, 2016.

A. M. Dudek, S. Pillay, A. S. Puschnik et al., "An alternate route for adeno-associated virus (AAV) entry independent of AAV Receptor," Journal of Virology, vol. 92, no. 7, pp. e02213–e02217, 2018.

S. Pillay and J. E. Carette, "Host determinants of adeno-associated viral vector entry," Current Opinion in Virology, vol. 24, pp. 124–131, 2017.

T. H. Davies and E. R. Sánchez, "FKBP52, The International Journal of Biochemistry & Cell Biology, vol. 37, no. 1, pp. 42–47, 2005.

C. B. Kang, Y. Hong, S. Dhe-Paganon, and H. S. Yoon, "FKBP family proteins: immunophilins with versatile biological functions," Neurosignals, vol. 16, no. 4, pp. 318–325, 2008.

C. L. Storer, C. A. Dickey, M. D. Galigniana, T. Rein, and M. B. Cox, "FKBP51 and FKBP52 in signaling and disease," Trends in Endocrinology & Metabolism, vol. 22, no. 12, pp. 481–490, 2011.

L. Liu, N. M. Oliveira, K. M. Cheney et al., "A whole genome screen for HIV restriction factors," Retrovirology, vol. 8, p. 94, 2011.

F. Jarczowski, G. Fischer, and F. Edlich, "FKBP36 forms complexes with clathrin and Hsp72 in spermatoocytes," Biochimie, vol. 47, no. 26, pp. 6946–6952, 2008.

N. R. Zgainar, S. A. De Leo, C. M. Lotufo, A. G. Erlejman, G. Piwien Pilipuk, and M. D. Galigniana, "Biological actions of the Hsp90-binding immunophilins FKBP51 and FKBP52," Biomolecules, vol. 9, no. 2, p. 52, 2019.

C. Hölscher, E. Sonntag, K. Henrich et al., "The SUMOylation pathway restricts gene transduction by adeno-associated viruses," PLOS Pathogens, vol. 11, no. 12, p. e1005281, 2015.

M. Brunet Simioni, A. De Thonel, A. Hammann et al., "Heat shock protein 27 is involved in SUMO-2/3 modification of heat shock factor 1 and thereby modulates the transcription factor activity," Oncogene, vol. 28, pp. 3332–3344, 2009.

A. K. Miträ, V. Agrahari, A. Mandal et al., "Novel delivery approaches for cancer therapeutics," Journal of Controlled Release, vol. 219, pp. 248–268, 2015.

A. M. Keeeler, M. K. ElMallah, and T. R. Flotte, "Gene therapy 2017: progress and future directions," Clinical and Translational Science, vol. 10, no. 4, pp. 242–248, 2017.

"Gene Therapy Clinical Trials Worldwide," Provided by the Journal of Gene Medicine, 2019, Available at: http://www.abedia.com/wiley/vectors.php.